ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
03 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.48 1.92M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 3.95p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £1.92 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.48.

Evgen Pharma Share Discussion Threads

Showing 5976 to 5999 of 13025 messages
Chat Pages: Latest  245  244  243  242  241  240  239  238  237  236  235  234  Older
DateSubjectAuthorDiscuss
29/11/2020
23:00
Interesting KingAlf. My view is I would like as much insight as possible into something that I am invested in. Your view that less is more is a very interesting contrarian concept. Can’t wait for your investment book .. what will you call it? Let us know! I am genuinely interested. Will it amount to a superlative front and back cover only (in keeping with your philosophy) or will you backtrack and include a contents page? Stipulating therein less or zero contents equals more value? Make sure less is more applies to the weight price ratio too!
bocker01
29/11/2020
21:35
Lol..we know that Ivor...:-)

Ps cheers bocker, strange days, those that were promoting another stock on the EVG thread at the expense of EVG , now want to start their own EVG thread because they don't like reasonable speculation on EVG that might have a negative impact on the stock they were promoting, and what's even more farcical is that their leader has stated that SFX-01 will never be approved for Covid-19, and so makes you wonder why on earth he would want to set up his own EVG thread when he has zero confidence in SFX-01 chances....ho ho ho...Gl :-)

moneymunch
29/11/2020
20:38
I'm definitely in the less is more camp and would welcome a split.
kingalf
29/11/2020
20:16
Gimmetheloot! Agreed. There’s a lot of posters from presumably the Gnome stable popping up only to have a go at Money! Like it or not he’s the most enthusiastic poster and produces much new information. In contrast his critics contribute vey little other than negativity and very little related to EVG. In between times there is of course a slanging match. If the thread splits it will be bad for those who are long but I’ve no problem in it splitting if it gets rid of those who are are more interested in personalities than the share. One thing is clear Money posts more about the share than personalities.
bocker01
29/11/2020
19:46
MM I would wait for it to break the following before buying more.

200-Day Moving Average 9.84p
50-Day Moving Average 10.76p

Strong resistance at around 10.50p, can see it touching these and drifting lower again in the short term as its over bought.

kingalf
29/11/2020
18:30
Cheers gimmetheloot, looking forward to plenty of upward momentum this coming week, back to double figures in anticipation of good things to come..:-)
moneymunch
29/11/2020
18:01
I’ve enjoyed reading MM’s post and if anybody disagrees with whoever just filter that person. No need to get into a slanging match!!
gimmetheloot
29/11/2020
17:48
I'm buying more tomorrow, Prof Rob Clarke's presentation 8th December on ER+ breast cancer: mechanisms of therapeutic resistance, is suggestive that an update could be close imho. Gla ;-) 
moneymunch
29/11/2020
17:30
Ivor Hunch and moneymuch, please both stop it, you have both made your point
timbo003
29/11/2020
17:25
Are you invested in EVG ???
moneymunch
29/11/2020
17:24
I've also noticed that you're beginning to pollute the EVG board over on London South East - I hope you don't wreck that as well.
ivor hunch
29/11/2020
17:18
I've posted plenty of info on proceedings since April so where've you been all this time???
moneymunch
29/11/2020
17:14
As I say you can, and do, write this board by yourself, for yourself.
....and it's very boring

ivor hunch
29/11/2020
17:07
Lol...Ivor, so which username do you mostly use???
moneymunch
29/11/2020
17:06
Lol...because that's what Bully's do when they don't get their own way, and stop being fictitious...:-)
moneymunch
29/11/2020
17:05
Yes, MM, but not my first post on ADVFM - member since 2000. In that time I've seen many boards wrecked by obsessional posters who've lost all sense of reality in their enthusiasm for one share. Ultimately more reflective and analytical investors simply stop logging in. You could write this whole board by yourself, for yourself.
ivor hunch
29/11/2020
16:55
I can’t understand why you’re all ganging up on MM! He’s our pharma expert.
hodhasharon
29/11/2020
16:52
Pmsl Ivor, at your first post on this thread...ha ha ha...;-)
moneymunch
29/11/2020
15:35
Nobby, yes please start a new board asap and we can filter one particular poster. This does happen on boards where one poster has become obsessed with a particular share and ramps it ad nauseum. As you have pointed out on many occasions this particular poster knows very little about drug development and constantly makes misleading statements. Unlike you, I do not have a background in pharma, but have a specialist within the family who has an important role in big pharma and we talk often.
As regards EVG I have a modest holding, think there is a genuine possibility that with time SXF-01 could be proven valuable as an anti-inflammatory, but also realise that all small drug developers are very high risk.
So let's have a new, intelligent board!

ivor hunch
29/11/2020
10:40
folks, I have updated the header and removed most of the outdated information and links, however there is limit to what I can do on this until the company updates their own web site and the new CEO breaks cover, but meanwhile I will look to include any sensible suggestions others may have for the header.
timbo003
29/11/2020
10:21
Speculate to Accumulate...or not??? ;-)
moneymunch
29/11/2020
09:25
>>> Moneymunch, the speculation is becoming repetitive and constant repetition is detering investors and potential investors visiting this thread.

In the absence of new information it serves no purpose other than to reignite old feuds, so in order to keep the thread on topic and readable it must stop.

timbo003
29/11/2020
09:17
and Bocker's contact with Evgen suggests that there will plenty of updates along the way......Gla Holders ...a very BIG week coming UP!!! .....imho....;-)


"Seems the trial has internal milestones throughout which EVG did not reveal to me. I was not surprised. But they did say that when the milestones are reached RNS’s will be follow. My question to them concerned publication of release of numbers partaking. Anyway it seems that there will be updates as we go along....

However, I am most impressed with their communication. Response within 3 hours. Unusual and to be commended."

moneymunch
29/11/2020
08:43
Plenty of internal reporting and confirmation that the trial is in phases and steps, and therefore entirely reasonable to speculate on early reporting on milestones during the trial....Gla ;-)

ps timbo and hardly pointless to speculate just because one poster isn't happy, the same poster who has already stated that SFX-01 will never be approved for Covid-19. Gl ;-)

moneymunch
Chat Pages: Latest  245  244  243  242  241  240  239  238  237  236  235  234  Older